Specifically, FOXO1 can suppress classic aerobic glycolysis (metabolic pattern required for tumor growth [199]), in part by inhibiting c-Myc, a transcription factor that is frequently upregulated in most cancers and drives cell cycle progression and anabolic metabolism [200,201]. Here, MYC is linked to neoplasm.